US79400X3052 - Common Stock
SALARIUS PHARMACEUTICALS INC
NASDAQ:SLRX (3/28/2024, 4:10:55 PM)
0.53
+0.04 (+8.16%)
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. The company is headquartered in Houston, Texas and currently employs 12 full-time employees. The company went IPO on 2015-01-29. The firm is focused on developing effective treatments for cancers with unmet medical needs. The company is developing treatments for cancers caused by dysregulated gene expression. The Company’s product portfolio includes seclidemstat, which is being studied as a potential treatment for pediatric cancers, sarcomas and other cancers with limited treatment options. The firm's pipeline consists of two primary compounds: SP-3164, a small-molecule protein degrader, and seclidemstat (SP-2577), a small-molecule inhibitor. SP-3164 is a next-generation cereblon-binding molecular glue (MG). SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold. The molecule was discovered using structure-based computational screening coupled with chemical screening.
SALARIUS PHARMACEUTICALS INC
2450 Holcombe Blvd Ste J-608
Houston TEXAS 77021
P: 13467720346
CEO: David J. Arthur
Employees: 12
Website: https://salariuspharma.com/
Let's explore the current happenings on the US markets on Tuesday. Below, you'll find the stocks exhibiting unusual volume in today's session.
Shares of Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) rose sharply in today’s pre-market trading following fourth-quarter results.
We are starting off the day with a breakdown of the biggest pre-market stock movers that traders need to know about on Monday morning.
SLRX stock results show that Salarius Pharmaceuticals beat analyst estimates for earnings per share the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Salarius Pharmaceuticals (NASDAQ:SLRX) just reported results for the fourth qua...
Patient Enrollment Resumed in the Investigator-initiated Phase 1/2 Clinical Trial of Seclidemstat in Combination with Azacitidine to Treat Hematologic...
Here you can normally see the latest stock twits on SLRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: